Astellas Loses Bid to Block Myrbetriq Copies During Patent Suit

A federal judge rejected Astellas Pharma Inc.’s requests to block Lupin’s and Zydus’ copies of the overactive-bladder treatment Myrbetriq during a patent-infringement suit, finding an injunction in a related appeal doesn’t change the court’s assessment that Astellas is unlikely to overcome invalidity arguments.

Judge Joseph F. Bataillon concluded the Japanese company isn’t likely to prove that US Patent No. 11,707,451 is invalid, according to an opinion issued Wednesday in the US District Court for the District of Delaware. The judge also said the monetary harm Astellas claimed from the pair of Indian generic-drug makers didn’t constitute “irreparable” damage, a key ...